Trial Profile
A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neovascularisation, a major risk factor of corneal graft rejection.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2015
Price :
$35
*
At a glance
- Drugs Aganirsen (Primary)
- Indications Corneal neovascularisation
- Focus Therapeutic Use
- Sponsors Laboratoires CTRS
- 24 Jul 2015 New trial record